Dublin-based Avadel Pharmaceuticals plc has made a name for itself as a leading biopharmaceutical company operating in the United States. With a focus on enhancing patients' lives through innovative treatments, Avadel's flagship product offering is its LUMRYZ formulation - a sodium oxybate solution - currently undergoing Phase 3 clinical trials to curtail daytime sleepiness and cataplexy in adult narcolepsy patients. The firm was originally known as Flamel Technologies SA, having been founded in 2015, but rebranded as Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc's ticker is AVDL
The company's shares trade on the NASDAQ stock exchange
They are based in Dublin, Ireland
There are 11-50 employees working at Avadel Pharmaceuticals plc
It is https://www.avadel.com/
Avadel Pharmaceuticals plc is in the Healthcare sector
Avadel Pharmaceuticals plc is in the Drug Manufacturers - Other industry
The following five companies are Avadel Pharmaceuticals plc's industry peers: